Downregulation of microRNA-182-5p contributes to renal cell carcinoma proliferation via activating the AKT/FOXO3a signaling pathway

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Xu, Xin ^a   Wu, Jian ^a   Li, Shiqi ^a   Hu, Zhenghui ^a   Xu, Xianglai ^a   Zhu, Yi ^a   Liang, Zhen ^a   Wang, Xiao ^a   Lin, Yiwei ^a   Mao, Yeqing ^a   Chen, Hong ^a   Luo, Jindan ^a   Liu, Ben ^a   Zheng, Xiangyi ^a   Xie, Liping ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

FLOT1; Microrna 182 5p; Proliferation; Renal cell carcinoma

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; FLOTILLIN 1; MICRORNA 182; MIR 182 5P; PROTEIN KINASE B; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; FLOTILLINS; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN; MEMBRANE PROTEIN; MICRORNA; MIRN182 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CELL CYCLE G0 PHASE; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HEK293 CELL LINE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MALE; NONHUMAN; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR VOLUME; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; KIDNEY TUMOR; METABOLISM; MOLECULAR GENETICS; MORTALITY; MOUSE; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; SURVIVAL;

ANIMALS; BASE SEQUENCE; CARCINOMA, RENAL CELL; CELL PROLIFERATION; EPIGENESIS, GENETIC; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; MEMBRANE PROTEINS; MICE; MICE, NUDE; MICRORNAS; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 84901852153     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-109     Document Type: Article

References (49)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917. 10.1002/ijc.25516, 21351269.
2. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001, 166:1611-1623. 10.1016/S0022-5347(05)65640-6, 11586189.
3. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000, 163:408-417. 10.1016/S0022-5347(05)67889-5, 10647643.
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297. 10.1016/S0092-8674(04)00045-5, 14744438.
5. Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet 2004, 5:396-400.
6. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233. 10.1016/j.cell.2009.01.002, 3794896, 19167326.
7. Juan D, Alexe G, Antes T, Liu H, Madabhushi A, Delisi C, Ganesan S, Bhanot G, Liou LS. Identification of a microRNA panel for clear-cell kidney cancer. Urology 2010, 75:835-841. 10.1016/j.urology.2009.10.033, 20035975.
8. Huang Y, Dai Y, Yang J, Chen T, Yin Y, Tang M, Hu C, Zhang L. Microarray analysis of microRNA expression in renal clear cell carcinoma. Eur J Surg Oncol 2009, 35:1119-1123. 10.1016/j.ejso.2009.04.010, 19443172.
9. Jung M, Mollenkopf HJ, Grimm C, Wagner I, Albrecht M, Waller T, Pilarsky C, Johannsen M, Stephan C, Lehrach H, Nietfeld W, Rudel T, Jung K, Kristiansen G. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med 2009, 13:3918-3928. 10.1111/j.1582-4934.2009.00705.x, 19228262.
10. Yi Z, Fu Y, Zhao S, Zhang X, Ma C. Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues. J Cancer Res Clin Oncol 2010, 136:855-862. 10.1007/s00432-009-0726-x, 19921256.
11. Chow TF, Youssef YM, Lianidou E, Romaschin AD, Honey RJ, Stewart R, Pace KT, Yousef GM. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem 2010, 43:150-158. 10.1016/j.clinbiochem.2009.07.020, 19646430.
12. Yamamura S, Saini S, Majid S, Hirata H, Ueno K, Chang I, Tanaka Y, Gupta A, Dahiya R. MicroRNA-34a suppresses malignant transformation by targeting c-Myc transcriptional complexes in human renal cell carcinoma. Carcinogenesis 2012, 33:294-300. 10.1093/carcin/bgr286, 3271269, 22159222.
13. Doberstein K, Steinmeyer N, Hartmetz AK, Eberhardt W, Mittelbronn M, Harter PN, Juengel E, Blaheta R, Pfeilschifter J, Gutwein P. MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients. Neoplasia 2013, 15:218-230. 3579323, 23441135.
14. Majid S, Saini S, Dar AA, Hirata H, Shahryari V, Tanaka Y, Yamamura S, Ueno K, Zaman MS, Singh K, Chang I, Deng G, Dahiya R. MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer Res 2011, 71:2611-2621. 10.1158/0008-5472.CAN-10-3666, 3940352, 21330408.
15. Saini S, Yamamura S, Majid S, Shahryari V, Hirata H, Tanaka Y, Dahiya R. MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. Cancer Res 2011, 71:6208-6219. 10.1158/0008-5472.CAN-11-0073, 3940359, 21852381.
16. Hidaka H, Seki N, Yoshino H, Yamasaki T, Yamada Y, Nohata N, Fuse M, Nakagawa M, Enokida H. Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget 2012, 3:44-57. 3292891, 22294552.
17. Hirata H, Hinoda Y, Ueno K, Nakajima K, Ishii N, Dahiya R. MicroRNA-1826 directly targets beta-catenin (CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer. Carcinogenesis 2012, 33:501-508. 10.1093/carcin/bgr302, 3291860, 22180573.
18. Hirata H, Ueno K, Shahryari V, Deng G, Tanaka Y, Tabatabai ZL, Hinoda Y, Dahiya R. MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer. PLoS One 2013, 8:e55502. 10.1371/journal.pone.0055502, 3559583, 23383207.
19. Chiang CH, Hou MF, Hung WC. Up-regulation of miR-182 by beta-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK. Biochim Biophys Acta 1830, 2013:3067-3076.
20. Hirata H, Ueno K, Shahryari V, Tanaka Y, Tabatabai ZL, Hinoda Y, Dahiya R. Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer. PLoS One 2012, 7:e51056. 10.1371/journal.pone.0051056, 3511415, 23226455.
21. Wang J, Li J, Shen J, Wang C, Yang L, Zhang X. MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma. BMC Cancer 2012, 12:227. 10.1186/1471-2407-12-227, 3492170, 22681717.
22. Cekaite L, Rantala JK, Bruun J, Guriby M, Agesen TH, Danielsen SA, Lind GE, Nesbakken A, Kallioniemi O, Lothe RA, Skotheim RI. MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer. Neoplasia 2012, 14:868-879. 3459282, 23019418.
23. Tang T, Wong HK, Gu W, Yu MY, To KF, Wang CC, Wong YF, Cheung TH, Chung TK, Choy KW. MicroRNA-182 plays an onco-miRNA role in cervical cancer. Gynecol Oncol 2013, 129:199-208. 10.1016/j.ygyno.2012.12.043, 23313739.
24. Wang YQ, Guo RD, Guo RM, Sheng W, Yin LR. MicroRNA-182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas. J Cell Biochem 2013, 114:1464-1473. 10.1002/jcb.24488, 23296900.
25. Song L, Liu L, Wu Z, Li Y, Ying Z, Lin C, Wu J, Hu B, Cheng SY, Li M, Li J. TGF-beta induces miR-182 to sustain NF-kappaB activation in glioma subsets. J Clin Invest 2012, 122:3563-3578. 10.1172/JCI62339, 3589141, 23006329.
26. Yan D, Dong XD, Chen X, Yao S, Wang L, Wang J, Wang C, Hu DN, Qu J, Tu L. Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2. PLoS One 2012, 7:e40967. 10.1371/journal.pone.0040967, 3407171, 22848417.
27. Sun Y, Fang R, Li C, Li L, Li F, Ye X, Chen H. Hsa-mir-182 suppresses lung tumorigenesis through down regulation of RGS17 expression in vitro. Biochem Biophys Res Commun 2010, 396:501-507. 10.1016/j.bbrc.2010.04.127, 20420807.
28. Kong WQ, Bai R, Liu T, Cai CL, Liu M, Li X, Tang H. MicroRNA-182 targets cAMP-responsive element-binding protein 1 and suppresses cell growth in human gastric adenocarcinoma. FEBS J 2012, 279:1252-1260.
29. Chow TF, Mankaruos M, Scorilas A, Youssef Y, Girgis A, Mossad S, Metias S, Rofael Y, Honey RJ, Stewart R, Pace KT, Yousef GM. The miR-17-92 cluster is over expressed in and has an oncogenic effect on renal cell carcinoma. J Urol 2010, 183:743-751. 10.1016/j.juro.2009.09.086, 20022054.
30. Osanto S, Qin Y, Buermans HP, Berkers J, Lerut E, Goeman JJ, van Poppel H. Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing. PLoS One 2012, 7:e38298. 10.1371/journal.pone.0038298, 3380046, 22745662.
31. Chien CH, Sun YM, Chang WC, Chiang-Hsieh PY, Lee TY, Tsai WC, Horng JT, Tsou AP, Huang HD. Identifying transcriptional start sites of human microRNAs based on high-throughput sequencing data. Nucleic Acids Res 2011, 39:9345-9356. 10.1093/nar/gkr604, 3241639, 21821656.
32. Liu S, Howell PM, Riker AI. Up-regulation of miR-182 expression after epigenetic modulation of human melanoma cells. Ann Surg Oncol 2013, 20:1745-1752. 10.1245/s10434-012-2467-3, 22752337.
33. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci 2007, 120:2479-2487. 10.1242/jcs.001222, 17646672.
34. Tenbaum SP, Ordonez-Moran P, Puig I, Chicote I, Arques O, Landolfi S, Fernandez Y, Herance JR, Gispert JD, Mendizabal L, Aguilar S, Ramón Cajal S, Schwartz S, Vivancos A, Espín E, Rojas S, Baselga J, Tabernero J, Muñoz A, Palmer HG. beta-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 2012, 18:892-901. 10.1038/nm.2772, 22610277.
35. Santo EE, Stroeken P, Sluis PV, Koster J, Versteeg R, Westerhout EM. FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma. Cancer Res 2013, 73:2189-2198. 10.1158/0008-5472.CAN-12-3767, 23378341.
36. Lin C, Wu Z, Lin X, Yu C, Shi T, Zeng Y, Wang X, Li J, Song L. Knockdown of FLOT1 impairs cell proliferation and tumorigenicity in breast cancer through upregulation of FOXO3a. Clin Cancer Res 2011, 17:3089-3099. 10.1158/1078-0432.CCR-10-3068, 21447726.
37. Massague J. G1 cell-cycle control and cancer. Nature 2004, 432:298-306. 10.1038/nature03094, 15549091.
38. Medema RH, Kops GJ, Bos JL, Burgering BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000, 404:782-787. 10.1038/35008115, 10783894.
39. Roy SK, Srivastava RK, Shankar S. Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal 2010, 5:10. 10.1186/1750-2187-5-10, 2915986, 20642839.
40. Weidinger C, Krause K, Mueller K, Klagge A, Fuhrer D. FOXO3 is inhibited by oncogenic PI3K/Akt signaling but can be reactivated by the NSAID sulindac sulfide. J Clin Endocrinol Metab 2011, 96:E1361-1371. 10.1210/jc.2010-2453, 21752881.
41. Bickel PE, Scherer PE, Schnitzer JE, Oh P, Lisanti MP, Lodish HF. Flotillin and epidermal surface antigen define a new family of caveolae-associated integral membrane proteins. J Biol Chem 1997, 272:13793-13802. 10.1074/jbc.272.21.13793, 9153235.
42. Volonte D, Galbiati F, Li S, Nishiyama K, Okamoto T, Lisanti MP. Flotillins/cavatellins are differentially expressed in cells and tissues and form a hetero-oligomeric complex with caveolins in vivo. Characterization and epitope-mapping of a novel flotillin-1 monoclonal antibody probe. J Biol Chem 1999, 274:12702-12709. 10.1074/jbc.274.18.12702, 10212252.
43. Xiong P, Xiao LY, Yang R, Guo Q, Zhao YQ, Li W, Sun Y. Flotillin-1 promotes cell growth and metastasis in oral squamous cell carcinoma. Neoplasma 2013, 60:395-405. 10.4149/neo_2013_051, 23581411.
44. Song L, Gong H, Lin C, Wang C, Liu L, Wu J, Li M, Li J. Flotillin-1 promotes tumor necrosis factor-alpha receptor signaling and activation of NF-kappaB in esophageal squamous cell carcinoma cells. Gastroenterology 2012, 143:995-1005. e1012, 10.1053/j.gastro.2012.06.033, 22732732.
45. Zhang SH, Wang CJ, Shi L, Li XH, Zhou J, Song LB, Liao WT. High Expression of FLOT1 Is Associated with Progression and Poor Prognosis in Hepatocellular Carcinoma. PLoS One 2013, 8:e64709. 10.1371/journal.pone.0064709, 3694104, 23840303.
46. Zhang PF, Zeng GQ, Hu R, Li C, Yi H, Li MY, Li XH, Qu JQ, Wan XX, He QY, Li JH, Chen Y, Ye X, Li JY, Wang YY, Feng XP, Xiao ZQ. Identification of flotillin-1 as a novel biomarker for lymph node metastasis and prognosis of lung adenocarcinoma by quantitative plasma membrane proteome analysis. J Proteomics 2012, 77:202-214.
47. Raimondo F, Valerio DT, Magni F, Perego R, Bianchi C, Sarto C, Casellato S, Fasoli E, Ferrero S, Cifola I. Caveolin-1 and flotillin-1 differential expression in clinical samples of renal cell carcinoma. The Open Proteomics J 2008, 1:87-98.
48. Chen H, Lin YW, Mao YQ, Wu J, Liu YF, Zheng XY, Xie LP. MicroRNA-449a acts as a tumor suppressor in human bladder cancer through the regulation of pocket proteins. Cancer Lett 2012, 320:40-47. 10.1016/j.canlet.2012.01.027, 22266187.
49. Xu X, Chen H, Lin Y, Hu Z, Mao Y, Wu J, Zhu Y, Li S, Zheng X, Xie L. MicroRNA-409-3p inhibits migration and invasion of bladder cancer cells via targeting c-Met. Mol Cells 2013, 36:62-68. 10.1007/s10059-013-0044-7, 23820886.